Trieu Jeffrey, Dobbin Nina, Henderson Sarah B, McVea David
Environmental Health Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada.
National Collaborating Centre for Environmental Health, Vancouver, BC, Canada.
Can J Public Health. 2025 Apr 7. doi: 10.17269/s41997-025-01022-8.
The objective of this study was to examine whether cannabis exposure calls to the British Columbia Drug and Poison Information Centre (DPIC) were impacted by the legalization of non-medical cannabis in Canada.
We fit interrupted time series models to monthly counts of cannabis cases from 2013 to 2021, stratified by age and cannabis form. We set the intervention month to October 2018 legalization for cases involving inhaled dried cannabis and ingestible oils and capsules. We set the intervention month to January 2020 for cases involving edibles and inhaled concentrates to reflect their commercial rollout after their October 2019 legalization.
DPIC managed 3989 cases involving cannabis exposure between 2013 and 2021. The rate (95% CI) of all cannabis cases increased by 17% (14%, 20%) annually from 2013 to October 2018 legalization. The highest pre-legalization increase was in pediatric edible cases with 52% (36%, 69%) and 57% (35%, 82%) annual increases among children aged 5 and under and 6 to 12, respectively. Upon legalization, the rate of cases consuming oil and capsule products spiked by 26% (- 19%, 96%) followed by a decrease, but remaining higher than the pre-legalization rate. Legalization did not have an immediate effect on the rate of cases involving edibles or inhaled cannabis, which all continued to increase post-legalization, albeit at slower rates.
Regardless of the contributing factors to cannabis case trends at DPIC, these data highlight the importance of poisoning prevention policies, promotion of low-risk use, and routine surveillance.
本研究的目的是调查加拿大非医用大麻合法化是否影响了拨打不列颠哥伦比亚省药物与毒物信息中心（DPIC）的大麻暴露相关电话。
我们对2013年至2021年按年龄和大麻形式分层的大麻病例月度计数拟合了中断时间序列模型。对于涉及吸入式干大麻以及可食用油和胶囊的病例，我们将干预月份设定为2018年10月合法化之时。对于涉及可食用产品和吸入式浓缩物的病例，我们将干预月份设定为2020年1月，以反映其在2019年10月合法化后的商业推广。
2013年至2021年期间，DPIC处理了3989例大麻暴露相关病例。从2013年至2018年10月合法化，所有大麻病例的发生率（95%置信区间）每年增长17%（14%，20%）。合法化前增长最高的是儿科可食用产品病例，5岁及以下儿童和6至12岁儿童的年增长率分别为52%（36%，69%）和57%（35%，82%）。合法化后，食用油和胶囊产品消费病例的发生率飙升了26%（-19%，96%），随后下降，但仍高于合法化前的发生率。合法化对涉及可食用产品或吸入式大麻病例的发生率没有立即影响，这些病例在合法化后都继续增加，尽管增速较慢。
无论DPIC大麻病例趋势的促成因素如何，这些数据都凸显了中毒预防政策、促进低风险使用以及常规监测的重要性。
